\
&
Contact us
\
&
Contact us
Published on | 4 years ago
Last updated on | 3 weeks ago
pascal.verheye@vlaio.be
There are 4 attachments connected to this article.
Attachments are only accessible for people with an account on the NCP Flanders website.
The goal of the Ocean's Mission is to restore our oceans and waters by 2030.
Man-made changes are putting our ocean and waters at serious risk leading to pollution, biodiversity loss and extreme weather events such as floods, droughts and heatwaves.
Therefore, the 3 Mission objectives are :
The Ocean Mission Implementation Plan aims to be the operational blueprint for how the Commission will deliver on the overall objective of the Mission on Ocean.
Open & forthcoming Ocean and Waters Mission calls can be consulted on the Funding & Tenders Portal or in the work program at the right of this webpage.
A portfolio of projects & results on water research and innovation funded under past framework programmes FP6 (2002-2006), FP7 (2007-2013) and Horizon 2020 (2014-2020) and the current Horizon Europe framework programme (2021-2027) can be found in the CORDIS database.
A Synergy Info Pack showcases 34 research projects funded through the complementary programmes of Horizon 2020 (including SME Instrument), LIFE and EMFF.
Ocean and Water-related projects supported by European Regions can be found in the KOHESIO database.
Find it out here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
